Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

Monitoring and Side Effect Management of Antipsychotics in Children and Adolescents

AI Summary
  • Systematic monitoring of movement disorders and metabolic disturbances is essential to prevent harm in children and adolescents on antipsychotics.
  • Consider individual patient characteristics, risk factors, and drug properties when initiating antipsychotic therapy in paediatric patients.
  • Expect potential increased clozapine use after REMS discontinuation; clinicians must recognise clozapine side effects and consider long-acting injectables where appropriate.
Summarise with AI (MRCPsych/FRANZCP)

Child Adolesc Psychiatr Clin N Am. 2027 Jan;36(1):17-32. doi: 10.1016/j.chc.2026.08.002. Epub 2026 Sep 11.

ABSTRACT

Antipsychotics are frequently used in children and adolescents, and this population is at an increased risk of experiencing an adverse event when initiating antipsychotic therapy. Systematic monitoring and evaluation of antipsychotic-induced movement disorders and metabolic disturbances are imperative to prevent patient-harm. Individual patient characteristics and risk factors should be considered alongside individual drug properties when initiating antipsychotic agents. Clozapine use may increase in this patient population due to the discontinuation of the Risk Evaluation and Mitigation Strategies program, and clinicians should be aware of its potential side effects. Long-acting injectable antipsychotics may be optimal for some pediatric patients.

PMID:43051732 | DOI:10.1016/j.chc.2026.08.002

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD